Group 1 - Eli Lilly will pay ABL Bio $40 million for licensing, research, and collaboration [1] - Eli Lilly will also make a $15 million equity investment in ABL Bio [1] - The collaboration focuses on joint research utilizing ABL Bio's bispecific antibody platform "Grabody" [1]